Search Results - "Chumsri, S."

Butaphosphan and Cyanocobalamin Supplementation in Semen Extender on Chilled Boar Sperm Quality and Life Span by Suwimonteerabutr, J, Chumsri, S, Tummaruk, P, Nuntapaitoon, Morakot

“…The objective of the present study was to determine the effect of butaphosphan and cyanocobalamin supplementation in semen extender on chilled boar sperm…”
Get full text

Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling by Nakanishi, T, Chumsri, S, Khakpour, N, Brodie, A H, Leyland-Jones, B, Hamburger, A W, Ross, D D, Burger, A M

“…Background: The expression of side-population (SP) cells and their relation to tumour-initiating cells (T-ICs) have been insufficiently studied in breast…”
Get full text

Final analysis of the ALTTO trial: adjuvant trastuzumab in sequence or in combination with lapatinib in patients with HER2-positive early breast cancer [BIG 2-06/NCCTG N063D (Alliance)] by de Azambuja, E., Piccart-Gebhart, M., Fielding, S., Townend, J., Hillman, D.W., Colleoni, M., Roylance, R., Kelly, C.M., Lombard, J., El-Abed, S., Choudhury, A., Korde, L., Vicente, M., Chumsri, S., Rodeheffer, R., Ellard, S.L., Wolff, A.C., Holtschmidt, J., Lang, I., Untch, M., Boyle, F., Xu, B., Werutsky, G., Tujakowski, J., Huang, C.-S., Baruch, N.B., Bliss, J., Ferro, A., Gralow, J., Kim, S.-B., Kroep, J.R., Krop, I., Kuemmel, S., McConnell, R., Moscetti, L., Knop, A.S., van Duijnhoven, F., Gomez, H., Cameron, D., Di Cosimo, S., Gelber, R.D., Moreno-Aspitia, A.

“…Dual anti-human epidermal growth factor receptor 2 (HER2) blockade has improved the outcomes of patients with early and metastatic HER2-positive breast cancer…”
Get full text

A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells by Linn, Douglas E, Yang, Xi, Sun, Feng, Xie, Yingqiu, Chen, Hege, Jiang, Richeng, Chen, Hegang, Chumsri, Saranya, Burger, Angelika M, Qiu, Yun

“…Drug resistance remains a clinical challenge in cancer treatment due to poor understanding of underlying mechanisms. We have established several drug-resistant…”
Get full text

Can Breast MRI Select Patients for Treatment With Preoperative APBI? by Awan, M, Bellavance, E, Kesmodel, S, Ioffe, O, Campassi, C, Tkaczuk, K, Chumsri, S, Bao, T, Feigenberg, S

Get full text

Near 25% Complete Pathologic Response Following Preoperative Accelerated Partial Breast Radiation Therapy (APBI) Using 3-dimensional Conformal Radiation Therapy (3D CRT) by Feigenberg, S.J, Staats, P, Citron, W, Drogula, C, Cohen, R, Kesmodel, S, Bellavance, E, Chumsri, S, Tkaczuk, K, Regine, W

Get full text

Preoperative Accelerated Partial Breast Radiation Is Associated With Decreased Cd8+ Cells in Patients With Early Breast Cancer by Feigenberg, S.J, Christenson, E, Staats, P, Webb, T, Chumsri, S, Tkaczuk, K, Nichols, E, Kesmodel, S, Bellavance, E, Regine, W

Get full text

Equivalent Survival with Breast Conservation Therapy or Mastectomy in the Management of Young Women with Early-stage Breast Cancer by Mahmood, U, Morris, C, Neuner, G, Koshy, M, Kesmodel, S, Buras, R, Chumsri, S, Bao, T, Tkaczuk, K, Feigenberg, S

Get full text

Clinical utilities of aromatase inhibitors in breast cancer by Chumsri, Saranya

“…Aromatase is an enzyme that converts testosterones to estrogens. Inhibition of this enzyme has been shown to have several clinical utilities in breast cancer…”
Get full text

237P Real-world outcomes of hormone receptor-positive (HR+) HER2-negative (HER2-) metastatic breast cancer (mBC) with high tumor mutational burden (hTMB) treated with immune checkpoint inhibitors (ICI) by Chumsri, S., Sammons, S., Alder, L., Sokol, E., Danziger, N.A., Raskina, K., Schrock, A.B., Venstrom, J., Snow, T., Castellanos, E., Ochuonyo, E., Snider, J., Mcgregor, K.

Get full text

Assessing the Relationship between Residual Cancer Burden and the Tumor Immune-Microenvironment in Early-Stage, Hormone Receptor-Positive Breast Cancer Following Preoperative Radiation Therapy in MC1732 Clinical Trial by Seneviratne, D., DeWees, T.A., Buras, M.R., Beuerlein, W., Chumsri, S., Thompson, A., Thorpe, C.S., Vallow, L.A., Pockaj, B.A., Cronin, P.A., Halyard, M.Y., Vern-Gross, T., McGee, L.A., Mclaughlin, S., Zot, P., Vargas, C.E.

Get full text

777TiP Phase I study of LYL797, a ROR1-targeted CAR T-cell therapy with genetic and epigenetic reprogramming for the treatment of advanced solid tumors by Spigel, D.R., Murthy, H., Chumsri, S., Ganguly, B.J., Gong, L., Hiraragi, H., Larsen, E., Liu, W., Martell, L., Zhu, S., Bornman, I-M., Fitzsimmons, S., Barnum, E., Christiansen, S., Gillenwater, H.

Get full text

Effects of immune architecture on response to adjuvant capecitabine in triple negative breast cancer (FinXX trial) by Hinerfeld, D.A., Chumsri, S., Asleh, K., Brauer, H.A., Kachergus, J., Lauttia, S., Lindman, H., Nielsen, T., Joensuu, H., Thompson, A.

Get full text

221P Long-term outcomes of patients with node-negative, ≤3cm, HER2+ breast cancer (BC) enrolled in ALTTO by Eiger, D., Tsourti, Z., Caparica, R., Kassapian, M., Napoleone, S., Hultsch, S., Korde, L., Wang, Y., Chumsri, S., Pritchard, K., Untch, M., Bellet Ezquerra, M., Rosa, D.D., Moreno-Aspitia, A., Piccart, M., Dafni, U., de Azambuja, E.

Get full text

Abstract P3-11-05: Predictive gene signatures of adjuvant capecitabine benefit in triple negative breast cancer in the FinXX trial by Chumsri, S, Asleh, K, Brauer, HA, Mashadi-Hossein, A, Lauttia, LS, Lindman, H, Nielsen, TO, Joensuu, H, Thompson, EA

“…Abstract Background: Recent studies have demonstrated a benefit of adjuvant capecitabine in early stage breast cancer, particularly in patients with residual…”
Get full text

Abstract PD3-02: Incidence of late relapse in HER2-positive (HER2+) breast cancer patients receiving adjuvant trastuzumab: Combined analysis of NCCTG (Alliance) N9831 and NSABP (NRG) B31 by Chumsri, S, Li, Z, Serie, DJ, Mashadi-Hossein, A, Colon-Otero, G, Song, N, Pogue-Geile, K, Gavin, P, Paik, S, Moreno-Aspitia, A, Perez, EA, Thompson, EA

“…Abstract Background: Recent trials showed potential benefit of extended adjuvant endocrine therapy and relatively high risk of relapse after 5 years (yr) in…”
Get full text

Abstract P2-11-10: Epigenetic immune modulation by entinostat in breast cancer: Correlative analysis of ENCORE 301 trial by Chumsri, S, Lee, M-J, Tomita, Y, Lee, S, Tomita, S, Cruickshank, S, Ordentlich, P, Trepel, JB

“…Abstract Background: Entinostat, a class I HDAC inhibitor (HDACi), has shown promising activity in ENCORE 301, a randomized, placebo-controlled, phase II trial…”
Get full text

Abstract P2-08-14: Dissecting the effect of hormone receptor (HR) status expression in patients (pts) with HER2-positive (HER2+) early breast cancer (EBC): Exploratory analysis from the ALTTO (BIG 2-06) trial by Lambertini, M, Campbell, C, Gelber, RD, Viale, G, McCullough, A, Tonghua, L, Hilbers, F, Korde, LA, Werner, O, Chumsri, S, Jackisch, C, Wolff, AC, Vaz-Luis, I, Ferreira, AR, Prat, A, Moreno Aspitia, A, Piccart, M, Loi, S, de Azambuja, E

“…Abstract Background We investigated the clinical outcomes and behavior of HER2+ EBC according to centrally tested HR status in pts treated with modern…”
Get full text

Abstract OT3-02-08: Genetic analysis in blood, urine, stool and tumor samples from patients with advanced or metastatic estrogen receptor positive and HER2 negative breast cancer receiving palbociclib and endocrine therapy (PROMISE) by O'Sullivan, CC, Suman, VJ, Kalari, KR, Moyer, A, Sung, J, Moreno-Aspitia, A, Northfelt, DW, Liu, MC, Haddad, TC, Chumsri, S, Couch, FJ, Weinshilboum, RM, Wang, L, Goetz, MP

“…Abstract Background: Combining cyclin dependent 4/6 kinase inhibitors (CDK4/6i) with endocrine therapy (ET) has resulted in clinically significant improvements…”
Get full text

Abstract P1-07-01: Histone deacetylase inhibitor entinostat reverses epithelial to mesenchymal transition of breast cancer cells by reversing the repression of E-cadherin by Sabnis, GJ, Shah, P, Kazi, A, Gau, Y, Chumsri, S, Brodie, A

“…Abstract Loss of ERa in breast cancer correlates with poor prognosis, increased recurrence rates and higher incidence of metastasis. In our previous studies,…”
Get full text